All In Biotech

Drug Trial Radar · NCT04121143

A Clinical Study of SHR-1314 Injection in the Treatment of Moderate to Severe Plaque Psoriasis in Adults

Multicenter, Placebo-controlled, Parallel-randomized, Double-blind, Phase II Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of SHR-1314 Injection With Moderate to Severe Plaque Psoriasis in Adults

Last checked: Nov 19, 2026Latest source record: Mar 23, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

SuspendedPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Suspended

Enrollment

120

Planned (sponsor's estimate)

Start

Nov 9, 2019

Primary completion

Jun 30, 2020

Study completion Dec 30, 2020

Sponsor

Sponsor type
Industry
First posted
Oct 9, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, placebo-controlled, parallel-randomized, double-blind, phase II study to investigate the efficacy, safety, tolerability and Pharmacokinetics of SHR-1314 injection with moderate to severe plaque psoriasis in adults

Conditions

  • Plaque Psoriasis

Interventions

  • IL-17A AntagonistBiological

    SHR-1314 subcutaneous injection

  • PlacebosBiological

    placebo subcutaneous injection to maintain consistency and to prevent blindness

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of subjects reach to PASI 75 response at 16 weeksTime frame: 16 week

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Hengrui Pharmaceutical Co., Ltd.

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.